SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel. This ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization. Invitae is ...

A novel DNA test system that assesses a person's genetic predisposition for certain cancers —the first of its kind granted marketing authorization by the US Food and Drug Administration (FDA) — may ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

The FDA authorized marketing of the first DNA test to help detect hundreds of genetic variants associated with cancer predisposition. The Invitae Common Hereditary Cancers Panel tests DNA in a blood ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

First, a bit of background on this genetic testing expert. The company sells a wide variety of genetic tests that inform you of your risk for genetic disease or of passing a particular condition on if ...